Abbott Laboratories (ABT)
Market Price (3/15/2026): $108.0 | Market Cap: $187.8 BilSector: Health Care | Industry: Health Care Equipment
Abbott Laboratories (ABT)
Market Price (3/15/2026): $108.0Market Cap: $187.8 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.7%, Dividend Yield is 2.2% | Weak multi-year price returns2Y Excs Rtn is -39%, 3Y Excs Rtn is -54% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.7% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17%, CFO LTM is 9.6 Bil, FCF LTM is 7.4 Bil | Key risksABT key risks include [1] significant product liability exposure from ongoing infant formula lawsuits, Show more. | |
| Low stock price volatilityVol 12M is 23% | ||
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, Digital Health & Telemedicine, Aging Population & Chronic Disease, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.7%, Dividend Yield is 2.2% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17%, CFO LTM is 9.6 Bil, FCF LTM is 7.4 Bil |
| Low stock price volatilityVol 12M is 23% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, Digital Health & Telemedicine, Aging Population & Chronic Disease, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -39%, 3Y Excs Rtn is -54% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.7% |
| Key risksABT key risks include [1] significant product liability exposure from ongoing infant formula lawsuits, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Abbott Laboratories (ABT) stock has lost about 15% since 11/30/2025 because of the following key factors:
1. Abbott Laboratories missed Q4 2025 revenue estimates, reporting sales of $11.46 billion against analyst expectations of $11.8 billion, a 2.9% shortfall. This company-specific performance led to an immediate drop of approximately 5.5% in the stock price to $114.10 on January 22, 2026.
2. The company provided weaker-than-anticipated Q1 2026 earnings guidance and continued to face challenges in its Nutrition segment. Abbott projected Q1 2026 adjusted earnings per share (EPS) to be between $1.12 and $1.18, below the analyst consensus of $1.20. Furthermore, the Nutrition business experienced an 8.9% decline in sales during Q4 2025, influenced by reduced sales volumes and the discontinuation of the ZonePerfect product line.
Show more
1. Abbott Laboratories missed Q4 2025 revenue estimates, reporting sales of $11.46 billion against analyst expectations of $11.8 billion, a 2.9% shortfall. This company-specific performance led to an immediate drop of approximately 5.5% in the stock price to $114.10 on January 22, 2026.
2. The company provided weaker-than-anticipated Q1 2026 earnings guidance and continued to face challenges in its Nutrition segment. Abbott projected Q1 2026 adjusted earnings per share (EPS) to be between $1.12 and $1.18, below the analyst consensus of $1.20. Furthermore, the Nutrition business experienced an 8.9% decline in sales during Q4 2025, influenced by reduced sales volumes and the discontinuation of the ZonePerfect product line.
Show more
Stock Movement Drivers
Fundamental Drivers
The -15.8% change in ABT stock from 11/30/2025 to 3/14/2026 was primarily driven by a -53.8% change in the company's Net Income Margin (%).| (LTM values as of) | 11302025 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 128.25 | 108.03 | -15.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 43,843 | 44,328 | 1.1% |
| Net Income Margin (%) | 31.9% | 14.7% | -53.8% |
| P/E Multiple | 16.0 | 28.8 | 80.2% |
| Shares Outstanding (Mil) | 1,742 | 1,739 | 0.2% |
| Cumulative Contribution | -15.8% |
Market Drivers
11/30/2025 to 3/14/2026| Return | Correlation | |
|---|---|---|
| ABT | -15.8% | |
| Market (SPY) | -3.1% | 5.9% |
| Sector (XLV) | -5.0% | 39.3% |
Fundamental Drivers
The -17.8% change in ABT stock from 8/31/2025 to 3/14/2026 was primarily driven by a -54.6% change in the company's Net Income Margin (%).| (LTM values as of) | 8312025 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 131.41 | 108.03 | -17.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 43,109 | 44,328 | 2.8% |
| Net Income Margin (%) | 32.4% | 14.7% | -54.6% |
| P/E Multiple | 16.4 | 28.8 | 75.7% |
| Shares Outstanding (Mil) | 1,743 | 1,739 | 0.2% |
| Cumulative Contribution | -17.8% |
Market Drivers
8/31/2025 to 3/14/2026| Return | Correlation | |
|---|---|---|
| ABT | -17.8% | |
| Market (SPY) | 3.0% | 8.3% |
| Sector (XLV) | 9.5% | 41.3% |
Fundamental Drivers
The -20.3% change in ABT stock from 2/28/2025 to 3/14/2026 was primarily driven by a -53.9% change in the company's Net Income Margin (%).| (LTM values as of) | 2282025 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 135.47 | 108.03 | -20.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 41,950 | 44,328 | 5.7% |
| Net Income Margin (%) | 31.9% | 14.7% | -53.9% |
| P/E Multiple | 17.6 | 28.8 | 64.0% |
| Shares Outstanding (Mil) | 1,737 | 1,739 | -0.1% |
| Cumulative Contribution | -20.3% |
Market Drivers
2/28/2025 to 3/14/2026| Return | Correlation | |
|---|---|---|
| ABT | -20.3% | |
| Market (SPY) | 12.4% | 20.5% |
| Sector (XLV) | 1.9% | 45.4% |
Fundamental Drivers
The 12.6% change in ABT stock from 2/28/2023 to 3/14/2026 was primarily driven by a 19.4% change in the company's P/E Multiple.| (LTM values as of) | 2282023 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 95.90 | 108.03 | 12.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 43,653 | 44,328 | 1.5% |
| Net Income Margin (%) | 15.9% | 14.7% | -7.3% |
| P/E Multiple | 24.1 | 28.8 | 19.4% |
| Shares Outstanding (Mil) | 1,743 | 1,739 | 0.2% |
| Cumulative Contribution | 12.6% |
Market Drivers
2/28/2023 to 3/14/2026| Return | Correlation | |
|---|---|---|
| ABT | 12.6% | |
| Market (SPY) | 73.4% | 20.3% |
| Sector (XLV) | 23.3% | 49.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ABT Return | 31% | -21% | 2% | 5% | 13% | -12% | 11% |
| Peers Return | 22% | -9% | 4% | 10% | 18% | -9% | 37% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 80% |
Monthly Win Rates [3] | |||||||
| ABT Win Rate | 58% | 42% | 50% | 58% | 58% | 33% | |
| Peers Win Rate | 60% | 47% | 52% | 53% | 60% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| ABT Max Drawdown | -3% | -31% | -16% | -8% | -1% | -15% | |
| Peers Max Drawdown | -6% | -21% | -14% | -4% | -10% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, MDT, TMO, DHR, BSX. See ABT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/13/2026 (YTD)
How Low Can It Go
| Event | ABT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -36.2% | -25.4% |
| % Gain to Breakeven | 56.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -31.6% | -33.9% |
| % Gain to Breakeven | 46.2% | 51.3% |
| Time to Breakeven | 24 days | 148 days |
| 2018 Correction | ||
| % Loss | -11.7% | -19.8% |
| % Gain to Breakeven | 13.3% | 24.7% |
| Time to Breakeven | 50 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -30.6% | -56.8% |
| % Gain to Breakeven | 44.1% | 131.3% |
| Time to Breakeven | 1,053 days | 1,480 days |
Compare to JNJ, MDT, TMO, DHR, BSX
In The Past
Abbott Laboratories's stock fell -36.2% during the 2022 Inflation Shock from a high on 12/27/2021. A -36.2% loss requires a 56.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Abbott Laboratories (ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
AI Analysis | Feedback
The **Johnson & Johnson** of medical devices, diagnostics, and nutrition.
**Medtronic** for devices and diagnostics, also making nutrition products like **Nestle**.
AI Analysis | Feedback
- Established Pharmaceutical Products: Generic and branded pharmaceuticals treating a wide range of conditions from pain and gastrointestinal disorders to infections.
- Diagnostic Laboratory Systems: Comprehensive systems for immunoassay, clinical chemistry, hematology, and molecular diagnostics used in laboratories.
- Point-of-Care and Rapid Diagnostics: Devices and cartridges for quick, on-site testing for conditions like HIV, SARS-CoV-2, influenza, and cardiometabolic health.
- Nutritional Products: Specialized pediatric and adult nutritional formulations supporting various health needs.
- Cardiovascular Medical Devices: A broad portfolio of devices for rhythm management, electrophysiology, heart failure, vascular, and structural heart conditions.
- Diabetes Care Products: Innovative solutions and devices for managing diabetes.
- Neuromodulation Devices: Medical devices designed to manage chronic pain and movement disorders.
AI Analysis | Feedback
Abbott Laboratories (ABT) primarily sells its products to other companies and institutions within the healthcare sector rather than directly to individuals. Based on the company description, its major customers fall into the following categories:
-
Hospitals and Healthcare Systems: This category encompasses general hospitals, specialized clinics, and integrated delivery networks that purchase a wide range of Abbott's offerings. This includes established pharmaceutical products, medical devices (e.g., rhythm management, electrophysiology, heart failure, vascular, structural heart, and neuromodulation devices), diagnostic systems (for their in-house labs), and nutritional products for patient care.
-
Clinical Laboratories and Blood Banks: These entities are primary customers for Abbott's Diagnostic Products segment, which includes laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion, as well as molecular diagnostics systems for detecting and measuring infectious agents.
-
Pharmacies and Retail Distributors: These serve as crucial channels for the distribution of Abbott's established pharmaceutical products (generic pharmaceuticals), nutritional products (pediatric and adult formulas), and certain medical devices, such as diabetes care products (e.g., continuous glucose monitoring systems) and consumer self-test systems, to the end-users.
AI Analysis | Feedback
nullAI Analysis | Feedback
Robert B. Ford, Chairman and Chief Executive Officer
Robert B. Ford became Abbott's President and Chief Executive Officer in March 2020 and assumed the role of Chairman in December 2021. He originally joined Abbott in 1996 within the company's diabetes care business and has held various leadership roles across Abbott's nutrition and medical device businesses. As Executive Vice President of Medical Devices, he oversaw the integration of St. Jude Medical, which was Abbott's largest acquisition at the time, and led Abbott's diabetes care business, including the launch of FreeStyle® Libre. Prior to joining Abbott, Mr. Ford held a marketing position with Becton Dickinson Brazil.
Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer
Philip P. Boudreau was appointed Senior Vice President, Finance and Chief Financial Officer, effective September 1, 2023, and subsequently promoted to Executive Vice President, Finance and Chief Financial Officer, effective July 1, 2024. He joined Abbott in 1997 and has held various finance leadership roles across the Diagnostics, Diabetes, Nutrition, and Medical Devices businesses. Before his appointment as CFO, he served as Abbott's Vice President, Controller since 2020.
Lisa D. Earnhardt, Executive Vice President and Group President, Medical Devices
Lisa D. Earnhardt is Abbott's Executive Vice President and Group President, Medical Devices, a role she was appointed to in December 2023. She previously served as Executive Vice President, Medical Devices since 2019. Prior to joining Abbott, Ms. Earnhardt served as President and Chief Executive Officer of Intersect ENT from 2008. Earlier in her career, she was President of Boston Scientific's Cardiac Surgery division. She began her career providing management consulting services to healthcare provider organizations at APM/CSC Healthcare.
Hubert L. Allen, Executive Vice President, General Counsel and Secretary
Hubert L. Allen has served as Executive Vice President, General Counsel, and Secretary at Abbott Laboratories since January 2013. He joined Abbott in 2006 as Senior Counsel, supporting the Pharmaceutical Products Division. Throughout his tenure at Abbott, he has held various positions within the legal department, including Divisional Vice President and Associate General Counsel for the Pharmaceutical Products Group and Section Head in Abbott Nutrition. Prior to joining Abbott, Mr. Allen was an Assistant General Counsel at McKesson Corporation.
Jared Watkin, Executive Vice President, Diabetes Care
Jared Watkin is Abbott's Executive Vice President of Diabetes Care. A scientist by training, he previously led the research and development of Abbott's FreeStyle Libre continuous glucose monitoring technology. He is recognized for his contributions to creating innovative, next-generation technologies and digital health tools that aim to transform diabetes management and improve health outcomes.
AI Analysis | Feedback
Here are the key risks to the business of Abbott Laboratories:- Legal, Regulatory, and Product Recall Risks: Abbott Laboratories faces significant legal and regulatory scrutiny, particularly concerning its infant formula business, which has led to investigations by the Securities and Exchange Commission (SEC) and Federal Trade Commission (FTC), as well as numerous lawsuits alleging contamination and adverse health effects in infants. The company has also experienced Class I recalls, the most severe category, for medical devices such as the Amplatzer Steerable Delivery Sheath and glucose monitor sensors, due to safety concerns that have been linked to serious injuries and deaths. Compliance with extensive governmental regulations in the healthcare industry is costly, and any failure to adhere to these standards can result in substantial fines, product recalls, and damage to the company's reputation and financial stability.
- Competitive and Pricing Pressures from Government Policies: Abbott operates in a highly competitive healthcare market that is significantly influenced by government policies and cost containment initiatives, both domestically and internationally. These pressures include competitive bidding and global price controls, particularly in key markets like China and in the diagnostics segment, which can lead to price reductions and negatively impact Abbott's high-margin products. Additionally, the fading tailwind from the COVID-19 pandemic and the anticipated decline in COVID-19 testing revenue present a financial headwind, estimated by management to exceed $1 billion in 2025.
- Global Supply Chain Vulnerabilities: Abbott Laboratories relies on an extensive and intricate global supply chain for the discovery, development, manufacture, and sale of its healthcare products. This complex supply chain is vulnerable to disruptions caused by various macroeconomic conditions, including inflation and labor shortages. Such vulnerabilities can lead to manufacturing problems, production delays, increased operational costs, and ultimately, a negative impact on the company's profitability and competitive position.
AI Analysis | Feedback
nullAI Analysis | Feedback
Addressable Markets for Abbott Laboratories' Main Products and Services
Abbott Laboratories (symbol: ABT) operates across diverse healthcare segments, each with significant addressable markets globally.
Established Pharmaceutical Products
- The global pharmaceutical market, which includes established pharmaceutical products, was estimated at approximately $1.77 trillion in 2025, with projections to reach $1.88 trillion by 2026 and nearly $3 trillion by 2034.
Diagnostic Products
- The global in vitro diagnostics market size was estimated at USD 105.7 billion in 2024 and is expected to grow to USD 155.4 billion by 2034.
Nutritional Products
- The global medical nutrition market size was valued at USD 52.94 billion in 2025 and is estimated to reach USD 108.84 billion by 2034.
Medical Devices
- The broader global cardiovascular devices market was valued at approximately US$72.83 billion in 2023 and is projected to reach US$110.39 billion by 2029.
- The global cardiac rhythm management devices market size was estimated at USD 20.77 billion in 2024 and is projected to reach USD 36.19 billion by 2033.
- The global electrophysiology devices market size was estimated at USD 10.07 billion in 2023 and is projected to reach USD 25.00 billion by 2030.
- The global structural heart devices market size was estimated at USD 16.13 billion in 2024 and is projected to reach USD 50.99 billion by 2033.
- For diabetes care, specifically continuous glucose monitoring (CGM) devices, the global market was valued at USD 10.9 billion in 2024 and is projected to grow to USD 47.1 billion by 2034. The wider global diabetes care devices market was valued at USD 53.5 billion in 2024 and is projected to reach USD 167.5 billion by 2034.
- The global neuromodulation devices market size was estimated at USD 6.37 billion in 2025 and is projected to reach USD 13.93 billion by 2033.
AI Analysis | Feedback
Abbott Laboratories (ABT) is expected to drive future revenue growth over the next two to three years through several key areas:
- Continuous Glucose Monitoring (CGM) with FreeStyle Libre: The FreeStyle Libre platform is consistently highlighted as a significant contributor to growth within Abbott's diabetes care portfolio. This segment experienced 12% growth in the fourth quarter of 2025 and 17% for the full year, with sales exceeding $7.5 billion, driven by strong market fundamentals, cost leadership, and ongoing innovation leading to increased adoption. The company announced positive results from the FreeDM2 Randomized Controlled Trial demonstrating glucose management improvements with Libre technology.
- New Product Launches and Approvals in Medical Devices: The Medical Devices segment continues to be a strong performer, with double-digit sales growth. Specific innovations like the Volt™ PFA System and TactiFlex™ Duo Ablation Catheter in Electrophysiology, along with the Aveir™ leadless pacemaker in Rhythm Management, are expected to fuel continued expansion. Abbott received FDA approval for prone MRI use with neuromodulation systems in January 2026, expanding access for its chronic pain device portfolio.
- Expansion into Cancer Diagnostics via Exact Sciences Acquisition: Abbott's agreement to acquire Exact Sciences, expected to close in the second quarter of 2026, strategically positions the company to enter and lead in the fast-growing cancer diagnostics market. This acquisition is a significant move to expand Abbott's diagnostics footprint.
- Growth in Established Pharmaceutical Products (EPD) in Emerging Markets: The Established Pharmaceutical Products segment has shown growth, particularly with double-digit increases in markets such as India, Latin America, and the Middle East. Abbott is also initiating the launch sequence to bring biosimilars to emerging markets, which is expected to contribute to future growth.
- Nutrition Segment Recovery and New Product Introductions: While the Nutrition segment faced challenges in 2025, management anticipates a return to growth in the second half of 2026. This recovery is expected to be driven by a pivot towards volume-driven growth strategies and the launch of new products designed to meet evolving consumer preferences.
AI Analysis | Feedback
Share Repurchases
- Abbott's board authorized a share repurchase program of up to $5 billion of common shares in December 2021.
- In October 2024, a new share repurchase program of up to $7 billion of the company's common shares was authorized.
- Abbott repurchased $1.227 billion in 2023, $1.295 billion in 2024, and $893 million in 2025.
Share Issuance
No significant information available for share issuance over the last 3-5 years.
Inbound Investments
No significant information available for large inbound investments by third-parties in Abbott Laboratories over the last 3-5 years.
Outbound Investments
- In April 2023, Abbott acquired Cardiovascular Systems, Inc. (CSI), a developer of atherectomy systems for peripheral and coronary artery disease, for approximately $851 million to $890 million.
- Abbott acquired Bigfoot Biomedical in September 2023, focusing on smart insulin management systems for diabetes, expanding its presence in diabetes care.
- In November 2025, Abbott announced an agreement to acquire Exact Sciences Corp. for an estimated $21 billion to $23 billion, aiming to enhance its diagnostics segment, particularly in cancer testing.
Capital Expenditures
- Abbott's capital expenditures were $1.885 billion in 2021, $1.777 billion in 2022, $2.202 billion in 2023, $2.207 billion in 2024, and $2.171 billion in 2025.
- These expenditures were primarily for upgrading and expanding manufacturing and research and development facilities and equipment across various segments.
- Investments in information technology and laboratory instruments placed with customers also constituted a significant portion of capital expenditures.
Latest Trefis Analyses
Trade Ideas
Select ideas related to ABT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 6.5% | 6.5% | -1.0% |
| 09302022 | ABT | Abbott Laboratories | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 5.6% | 2.0% | -1.3% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 147.68 |
| Mkt Cap | 153.1 |
| Rev LTM | 39,906 |
| Op Inc LTM | 7,332 |
| FCF LTM | 5,852 |
| FCF 3Y Avg | 5,857 |
| CFO LTM | 7,552 |
| CFO 3Y Avg | 7,656 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.9% |
| Rev Chg 3Y Avg | 1.7% |
| Rev Chg Q | 8.0% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 18.9% |
| Op Mgn 3Y Avg | 18.4% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 22.1% |
| CFO/Rev 3Y Avg | 20.5% |
| FCF/Rev LTM | 16.8% |
| FCF/Rev 3Y Avg | 15.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 153.1 |
| P/S | 4.7 |
| P/EBIT | 20.4 |
| P/E | 27.4 |
| P/CFO | 21.4 |
| Total Yield | 4.8% |
| Dividend Yield | 1.1% |
| FCF Yield 3Y Avg | 3.3% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -7.8% |
| 3M Rtn | -15.3% |
| 6M Rtn | -4.5% |
| 12M Rtn | -10.7% |
| 3Y Rtn | 19.9% |
| 1M Excs Rtn | -6.5% |
| 3M Excs Rtn | -14.1% |
| 6M Excs Rtn | -8.6% |
| 12M Excs Rtn | -29.6% |
| 3Y Excs Rtn | -50.8% |
Segment Financials
Assets by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Goodwill and intangible assets | 29,755 | 32,494 | 33,253 | 35,970 | 38,528 |
| All other | 18,165 | 8,458 | 7,912 | 6,987 | 5,096 |
| Medical Devices | 9,472 | 9,029 | 7,844 | 7,261 | 6,893 |
| Cash and investments | 8,853 | 8,078 | 10,936 | 11,065 | 7,969 |
| Diagnostics | 7,678 | 7,767 | 7,985 | 7,699 | 7,696 |
| Nutritionals | 4,404 | 4,270 | 3,625 | 3,425 | 3,478 |
| Established Pharmaceutical | 3,087 | 3,118 | 2,883 | 2,789 | 2,888 |
| Total | 81,414 | 73,214 | 74,438 | 75,196 | 72,548 |
Price Behavior
Price Behavior
| Market Price | $108.03 | |
| Market Cap ($ Bil) | 188.2 | |
| First Trading Date | 04/06/1983 | |
| Distance from 52W High | -20.7% | |
| 50 Days | 200 Days | |
| DMA Price | $114.82 | $125.41 |
| DMA Trend | down | down |
| Distance from DMA | -5.9% | -13.9% |
| 3M | 1YR | |
| Volatility | 27.4% | 23.3% |
| Downside Capture | 25.93 | 15.53 |
| Upside Capture | -62.52 | -2.00 |
| Correlation (SPY) | 4.9% | 20.2% |
ABT Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.15 | -0.07 | -0.10 | 0.06 | 0.24 | 0.27 |
| Up Beta | 0.59 | 1.06 | 0.85 | 0.67 | 0.28 | 0.34 |
| Down Beta | 0.75 | 0.11 | -0.09 | 0.16 | 0.43 | 0.34 |
| Up Capture | 52% | -71% | -61% | -26% | -2% | 5% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 15 | 20 | 28 | 61 | 129 | 389 |
| Down Capture | -91% | -21% | -7% | -1% | 17% | 36% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 6 | 21 | 33 | 63 | 122 | 362 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABT | |
|---|---|---|---|---|
| ABT | -15.6% | 23.3% | -0.78 | - |
| Sector ETF (XLV) | 5.0% | 17.5% | 0.12 | 44.9% |
| Equity (SPY) | 19.6% | 18.9% | 0.81 | 20.3% |
| Gold (GLD) | 71.9% | 26.3% | 2.05 | 2.2% |
| Commodities (DBC) | 19.3% | 17.3% | 0.89 | -1.4% |
| Real Estate (VNQ) | 6.2% | 16.3% | 0.19 | 40.0% |
| Bitcoin (BTCUSD) | -15.3% | 44.2% | -0.25 | -0.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABT | |
|---|---|---|---|---|
| ABT | 0.5% | 22.0% | -0.03 | - |
| Sector ETF (XLV) | 7.5% | 14.5% | 0.33 | 62.2% |
| Equity (SPY) | 13.1% | 17.0% | 0.61 | 41.8% |
| Gold (GLD) | 24.1% | 17.3% | 1.14 | 5.8% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | -1.0% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 46.1% |
| Bitcoin (BTCUSD) | 6.3% | 56.7% | 0.33 | 12.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABT | |
|---|---|---|---|---|
| ABT | 12.8% | 23.5% | 0.51 | - |
| Sector ETF (XLV) | 10.1% | 16.5% | 0.50 | 72.2% |
| Equity (SPY) | 14.5% | 17.9% | 0.70 | 57.3% |
| Gold (GLD) | 14.4% | 15.6% | 0.77 | 4.0% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 11.1% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 47.2% |
| Bitcoin (BTCUSD) | 67.4% | 66.8% | 1.07 | 10.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 1/22/2026 | -10.0% | -12.2% | -7.1% |
| 10/15/2025 | -2.4% | -3.9% | -2.9% |
| 7/17/2025 | -8.5% | -4.5% | -1.9% |
| 4/16/2025 | 2.8% | 2.9% | 5.6% |
| 1/22/2025 | 0.8% | 9.1% | 14.0% |
| 10/16/2024 | 1.5% | 0.1% | -0.3% |
| 7/18/2024 | -4.4% | 2.5% | 6.0% |
| 4/17/2024 | -3.0% | -1.5% | -4.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 14 | 13 |
| # Negative | 15 | 10 | 11 |
| Median Positive | 3.3% | 3.4% | 5.6% |
| Median Negative | -2.6% | -2.1% | -3.7% |
| Max Positive | 7.8% | 9.1% | 14.0% |
| Max Negative | -10.0% | -12.2% | -8.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/20/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/21/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/16/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 11/01/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 05/03/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Shroff, Eric | Senior Vice President | Direct | Sell | 11252025 | 128.02 | 1,586 | 203,043 | 3,889,814 | Form |
| 2 | Boudreau, Philip P | EVP AND CFO | Direct | Sell | 8112025 | 134.55 | 5,550 | 746,758 | 6,862,505 | Form |
| 3 | Blount, Sally E | Direct | Sell | 5022025 | 129.66 | 2,600 | 337,116 | 4,415,960 | Form | |
| 4 | Earnhardt, Lisa D | EVP AND GROUP PRESIDENT | Direct | Sell | 3072025 | 133.82 | 91,167 | 12,199,968 | 9,625,405 | Form |
| 5 | Earnhardt, Lisa D | EVP AND GROUP PRESIDENT | Direct | Sell | 3072025 | 136.65 | 200 | 27,329 | 9,828,602 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.